AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2025-06-19T05:32:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown |
|---|
| Breakdown |
|---|
| Breakdown |
|---|
Sector: Healthcare Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NUZ Neurizon Therapeutics Limited |
0.01 6.25% | 0.17 | - | - | 45.47 | 6.20 | 8.72 | -22.5865 |
| CSL CSL Ltd |
-3.26 1.35% | 238.71 | 28.85 | 33.67 | 7.67 | 4.14 | 5.94 | 18.44 |
| TLX Telix Pharmaceuticals Ltd |
-0.75 2.91% | 25.00 | 183.21 | 21.01 | 10.96 | 15.11 | 10.80 | 91.38 |
| MSB Mesoblast Ltd |
-0.12 6.70% | 1.67 | - | 454.55 | 414.37 | 3.34 | 67.90 | -9.8623 |
| NEU Neuren Pharmaceuticals Ltd |
-0.48 3.72% | 12.44 | 13.00 | 81.97 | 8.10 | 4.86 | 7.25 | 8.80 |
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Suite 2, Melbourne, VIC, Australia, 3000
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael Thurn Ph.D. | MD, CEO & Director | NA |
| Mr. John Clark | Chief Operating Officer | NA |
| Dr. Nicky Wallis | Chief Scientific Officer | NA |
| Ms. Fiona Milner | General Manager of Epichem Pty Ltd | NA |
| Dr. Gary Pitt | Head of Chemistry | NA |
| Dr. James Rixson | Head of Production | NA |
| Dr. Herbert Brinkman | Head of Manufacturing | NA |
| Mr. Stefan Ross | Company Secretary | NA |
| Ms. Lidija Damjanovic | Head of Marketing & Corporate Affairs | NA |
| Dr. Chris Freitag M.D. | Chief Medical Advisor | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...